Stop asking.
Let the data tell.
94% of adverse drug reactions go undetected by spontaneous reporting. In the Vioxx case, the signal was in the data 3.5 years before the drug was pulled. Herald continuously scans millions of patient records for safety, efficacy, and commercial signals — and makes sure that doesn't happen again.
What changes.
What Herald actually monitors.
Safety, effectiveness, commercial, and health economic signals. Simultaneously. Across your entire real-world patient population.
Safety
- ADRs missed by spontaneous reporting
- Drug-drug interactions from real-world co-prescribing
- Population-specific safety profiles
- Long-term emerging risks
Catch safety signals years before spontaneous reporting surfaces them. Act on risk before it becomes a public crisis.
Effectiveness
- Comparative effectiveness vs. alternatives
- Subpopulation response differences
- Treatment sequence optimization
- Real-world vs. trial efficacy gaps
Know exactly where your drug wins and where it doesn’t, broken down by subpopulation. Updated continuously, not once a year.
Commercial
- Off-label prescribing patterns
- Treatment switching and discontinuation rates
- Market share shifts by geography and payer
- Medication adherence trends
See label expansion opportunities, competitive threats, and prescribing shifts as they happen. Not in next quarter’s report.
Health Economic
- Healthcare resource utilization changes
- Total cost of care trajectories
- Readmission rate patterns
- Downstream cost savings
Build your value-based contracting evidence in real-time. Walk into payer negotiations with data from last week, not last year.
Stop asking the data.
Let the data tell you.
Deploy Herald on your existing data infrastructure. Surface signals your competitors won't see for years.